4,450.00p+0.00 (+0.00%)28 Mar 2024, 17:15
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Bioventix PLC Fundamentals

Company NameBioventix PLCLast Updated2024-03-28
IndustryBiotechnologySectorHealthcare
Shares in Issue5.220 mMarket Cap£232.27 m
PE Ratio27.24Dividend per Share£1.36
Dividend Yield3.42Dividend Cover1.16
EPS£1.58EPS Growth (%)0.09
PEG0DPS Growth (%)0.1930
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.1499Cash Equity Ratio0.4815
Quick Ratio6.6946Current Ratio7.04
Price To Book Value20.3252ROCE0

Bioventix PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total
Interim2024-04-112024-04-26GBP0.6800
Prelim2023-11-092023-11-24GBP0.9000
Interim2023-04-062023-04-21GBP0.6200
Prelim2022-11-032022-11-18GBP0.7400
Interim2022-04-072022-04-22GBP0.5200
Prelim2021-10-282021-11-12GBP0.6200
Interim2021-04-082021-04-23GBP0.4300

Bioventix PLC Company Financials

Assets202320222021
Tangible Assets£575,726.00£694,370.00£843,720.00
Intangible Assets000
Investments£610,039.00£610,039.00£610,039.00
Total Fixed Assets£1.19 m£1.30 m£1.45 m
Stocks£565,366.00£461,815.00£332,459.00
Debtors£5.81 m£5.22 m£4.63 m
Cash & Equivalents£5.72 m£6.13 m£6.49 m
Other Assets000
Total Assets£13.28 m£13.12 m£12.91 m
Liabilities202320222021
Creditors within 1 year£1.20 m£1.25 m£1.01 m
Creditors after 1 year£18,224.00£44,276.00£78,084.00
Other Liabilities000
Total Liabilities£1.22 m£1.30 m£1.09 m
Net assets£12.06 m£11.82 m£11.82 m
Equity202320222021
Called up share capital£260,983.00£260,467.00£260,467.00
Share Premium£1.47 m£1.33 m£1.33 m
Profit / Loss£10.13 m£9.28 m£8.12 m
Other Equity£12.06 m£11.82 m£11.82 m
Preference & Minorities000
Total Capital Employed£12.06 m£11.82 m£11.82 m
Ratios202320222021
Debt Ratio000
Debt-to-Equity000
Assets / Equity1.14991.14991.1499
Cash / Equity0.48150.48150.4815
EPS£1.61£1.47£1.29
Cash Flow202320222021
Cash from operating activities£7.80 m£7.56 m£6.34 m
Cashflow before financing-£501,342.00-£361,383.00-£1.35 m
Increase in Cash-£410,831.00-£368,335.00-£1.58 m
Income202320222021
Turnover£12.82 m£11.72 m£10.93 m
Cost of sales£828,410.00£710,446.00£817,448.00
Gross Profit£11.99 m£11.01 m£10.11 m
Operating Profit£10.03 m£9.27 m£8.09 m
Pre-Tax profit£10.13 m£9.28 m£8.12 m

Bioventix PLC Company Background

SectorHealthcare
ActivitiesBioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others.
Latest Interim Date25 Mar 2024
Latest Fiscal Year End Date30 Oct 2023

Bioventix PLC Directors

AppointedNamePosition
2023-11-28Mr. Bruce Edward Heath Hiscock Executive Director,Chief Financial Officer
2023-11-10Mr. Ian James NicholsonNon-Executive Director,Chairman
2024-01-29Mr. Peter John HarrisonExecutive Director,Chief Executive Officer
2020-07-01Ms. Treena Joan TurnerNon-Executive Director,Finance Director
2023-11-10Mr. Nicholas John McCookeNon-Executive Director

Bioventix PLC Contact Details

Company NameBioventix PLC
Address27-28 Eastcastle Street, London, W1W 8DH
Telephone+44 1252728001
Websitehttp://www.bioventix.com

Bioventix PLC Advisors

SolicitorCharles Russell Speechlys LLP
Phone+44 2072035000
Nominated AdviserFinnCap
Phone+44 2072200500
Fax+44 2072200597
AuditorJames Cowper Kreston
Phone+44 1189590261
StockbrokerFinnCap
Phone+44 2072200500
Fax+44 2072200597
RegistrarShare Registrars Limited
Phone+44 1252821390
Fax+44 1252719232